Alys Pharmaceuticals Launches First-in-Class Clinical Trial for ALY-301, Targeting Chronic Urticaria Alys Pharmaceuticals begins its Phase 1/1b trial for ALY-301, a pioneering c-Kit inhibitor aimed at treating Chronic Urticaria, showing promise for patients.

Alys Pharmaceuticals Launches First-in-Class Clinical Trial for ALY-301, Targeting Chronic Urticaria #United_States #Boston #Alys_Pharmaceuticals #Chronic_Urticaria #ALY-301

Evommune Unveils Promising Phase 2 Data for EVO756 Targeting Chronic Urticaria Evommune, Inc. showcased compelling Phase 2 results for EVO756 at the EADV 2025 Congress, showing significant benefits for chronic urticaria patients.

Evommune Unveils Promising Phase 2 Data for EVO756 Targeting Chronic Urticaria #United_States #Palo_Alto #Evommune #EVO756 #Chronic_Urticaria

Evommune Unveils Phase 2 Data for EVO756 at EADV 2025 Congress in Paris Discover the exciting developments unveiled by Evommune regarding EVO756's Phase 2 clinical trial for chronic inducible urticaria, presented at EADV 2025.

Evommune Unveils Phase 2 Data for EVO756 at EADV 2025 Congress in Paris #United_States #Palo_Alto #Evommune #EVO756 #Chronic_Urticaria

Evommune's EVO756 Shows Promising Results in Treating Chronic Inducible Urticaria Through Phase 2 Trials Evommune has announced encouraging results from their Phase 2 trial of EVO756 for Chronic Inducible Urticaria, showcasing notable efficacy and safety. The drug may redefine treatment options for chronic inflammatory diseases.

Evommune's EVO756 Shows Promising Results in Treating Chronic Inducible Urticaria Through Phase 2 Trials #Evommune #EVO756 #Chronic_Urticaria

Evommune Commences Global Phase 2b Clinical Trial for EVO756 to Treat Chronic Spontaneous Urticaria Evommune begins a global Phase 2b trial for EVO756, targeting chronic spontaneous urticaria (CSU) with expected data in mid-2026. This study aims to provide effective treatment options.

Evommune Commences Global Phase 2b Clinical Trial for EVO756 to Treat Chronic Spontaneous Urticaria #United_States #Palo_Alto #Evommune #EVO756 #Chronic_Urticaria